PIK3CA and head and neck squamous cell carcinoma: Similar approaches, including phosphoinositide 3-kinase (PI3K) inhibitors, have also been initiated in HNSCC patients, including OPSCC, with recurrent disease (e.g., NCT01602315 and NCT02537223).